# Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)

> **NCT02764125** · PHASE2 · COMPLETED · sponsor: **Orion Corporation, Orion Pharma** · enrollment: 84 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Stalevo
- **DRUG:** levodopa MR

## Key facts

- **NCT ID:** NCT02764125
- **Lead sponsor:** Orion Corporation, Orion Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-08
- **Primary completion:** 2018-03-27
- **Final completion:** 2018-03-27
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2018-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02764125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02764125, "Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02764125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*